2024-10-26 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis

**1. Performance Comparison with S&P 500 (VOO)**

Eli Lilly and Co (LLY) is a pharmaceutical company known for its diverse portfolio of medicines, including diabetes treatments, cancer therapies, and other innovative drugs. 

**Cumulative Return:**
* LLY: 856.19%
* VOO: 135.48%
* **Difference**: 720.71% (**89.53%** of the historical range)

LLY has significantly outperformed the S&P 500,  demonstrating strong growth potential compared to the broader market. It currently sits in the top 90% of its historical performance relative to the S&P 500.

**2. Recent Price Movement**

* **Closing price:** 891.32 (Last-market: 894.73)
* **5-day Moving Average:** 904.93
* **20-day Moving Average:** 904.4
* **60-day Moving Average:** 906.83

The stock is currently trading below its 5, 20, and 60-day moving averages, suggesting potential short-term weakness. 

**3. Technical Indicators**

* **RSI:** 51.77 
* **PPO:** -0.18 
* **Delta_Previous_Relative_Divergence:** -2.95 (**Downward Trend**)
* **Expected Return:** 96.56% 

The RSI indicates a slightly oversold condition. The PPO suggests a bearish signal. The recent downward trend in relative divergence indicates a possible short-term correction. However, the high expected return suggests strong long-term potential.

**4. Recent Earnings and Outlook**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 3.29 | 11.30 B$ |
| 2024-04-30 | 2.49 | 8.77 B$ |
| 2023-11-02 | -0.06 | 9.50 B$ |
| 2023-08-08 | 1.96 | 8.31 B$ |
| 2024-08-08 | 1.96 | 8.31 B$ |

The most recent earnings (2024-08-08) showed strong performance with an EPS of 3.29, exceeding expectations. Continued strong growth in key areas like diabetes and oncology, fueled by innovative products like Mounjaro and Trulicity, has driven this positive performance. Analyst expectations for 2025 remain positive, reflecting optimism about the company's future growth.

**5. News and Recent Issues**

* **Recent Earnings Announcement (2024-08-08):** LLY exceeded earnings expectations with strong revenue growth driven by its diabetes and oncology portfolios. 
* **Market Outlook:** Analyst opinions are generally positive, citing LLY's strong pipeline of promising drug candidates and its established position in key markets. 
* **Performance Highlights:**  The stock has been performing well, with a year-to-date return exceeding 50%. However, the recent dip in price suggests a potential short-term correction.  

**6. Summary**

LLY demonstrates strong long-term growth potential, fueled by its successful drug portfolio and promising pipeline.  While the recent short-term price action suggests a potential correction,  the long-term outlook remains positive. The company's high expected return and recent earnings beat solidify its position as a strong performer.

**7. Recommendations**

Given the strong long-term performance, positive analyst sentiment, and recent earnings beat, LLY presents a compelling investment opportunity for investors seeking exposure to the pharmaceutical sector.  The recent dip in price could offer an attractive entry point for long-term investors. However, potential short-term volatility should be considered. 
